Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up

[1]  L. Lunsford,et al.  Primary versus postoperative stereotactic radiosurgery for acromegaly: a multicenter matched cohort study. , 2020, Journal of neurosurgery.

[2]  S. Kunwar,et al.  Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. , 2019, Journal of neurosurgery.

[3]  M. Gemma,et al.  Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly , 2019, Pituitary.

[4]  H. Dufour,et al.  Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly , 2018, Pituitary.

[5]  B. Zhu,et al.  Association between acromegaly and a single nucleotide polymorphism (rs2854744) in the IGFBP3 gene , 2018, BMC Medical Genetics.

[6]  S. Yarman,et al.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas , 2018, Pituitary.

[7]  B. Fox,et al.  The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes , 2018, Clinical Cancer Research.

[8]  G. Johannsson,et al.  Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. , 2018, European journal of endocrinology.

[9]  S. Yin,et al.  Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience , 2018, Clinical Neurology and Neurosurgery.

[10]  S. Yin,et al.  Invasive Pituitary Adenoma-Derived Tumor-Associated Fibroblasts Promote Tumor Progression both In Vitro and In Vivo. , 2017, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[11]  M. Lopes,et al.  The 2017 World Health Organization classification of tumors of the pituitary gland: a summary , 2017, Acta Neuropathologica.

[12]  O. Mete,et al.  Overview of the 2017 WHO Classification of Pituitary Tumors , 2017, Endocrine Pathology.

[13]  P. Beck‐Peccoz,et al.  Central hypothyroidism — a neglected thyroid disorder , 2017, Nature Reviews Endocrinology.

[14]  V. De Sanctis,et al.  The Diagnostic Approach to Central Adrenocortical Insufficiency (CAI) in Thalassemia , 2016, Mediterranean journal of hematology and infectious diseases.

[15]  J. Honegger,et al.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas , 2016, Endocrine Pathology.

[16]  M. Maghnie,et al.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism—pathogenesis, diagnosis and treatment , 2015, Nature Reviews Endocrinology.

[17]  J. Sheehan,et al.  Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype , 2015, Pituitary.

[18]  K. Lillehei,et al.  Growth hormone tumor histological subtypes predict response to surgical and medical therapy , 2015, Endocrine.

[19]  J. Dietemann,et al.  Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. , 2015, Endocrine-related cancer.

[20]  E. Knosp,et al.  Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. , 2015, Journal of neurosurgery.

[21]  A. Kara,et al.  Evaluation of hypothalamic–pituitary function in children following acute bacterial meningitis , 2015, Pituitary.

[22]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  M. Fleseriu,et al.  Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial , 2014, Endocrine.

[24]  A. Heaney.  Management of aggressive pituitary adenomas and pituitary carcinomas , 2014, Journal of Neuro-Oncology.

[25]  D. McArthur,et al.  The pituitary stalk effect: is it a passing phenomenon? , 2014, Journal of Neuro-Oncology.

[26]  R. Clayton,et al.  A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. , 2014, The Journal of clinical endocrinology and metabolism.

[27]  S. Işık,et al.  Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. , 2013, Journal of neurosurgery.

[28]  M. Gadelha,et al.  Giant prolactinomas: the therapeutic approach , 2013, Clinical endocrinology.

[29]  L. Persani.  Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges , 2012 .

[30]  Eun Jig Lee,et al.  Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. , 2012, Neurosurgery.

[31]  Wan-Yuo Guo,et al.  MIB-1 labeling index correlated with magnetic resonance imaging detected tumor volume doubling time in pituitary adenoma. , 2010, European journal of endocrinology.

[32]  S. Melmed.  Medical progress: Acromegaly. , 2006, The New England journal of medicine.

[33]  N. Karavitaki,et al.  Do the limits of serum prolactin in disconnection hyperprolactinaemia need re‐definition? A study of 226 patients with histologically verified non‐functioning pituitary macroadenoma , 2006, Clinical endocrinology.

[34]  M. Losa,et al.  Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery 2005;56:1222-1233 , 2005, Neurosurgery.

[35]  R. Fahlbusch,et al.  The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.

[36]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[37]  G. Neuloh,et al.  Reliability of the oral glucose tolerance test in the early postoperative assessment of acromegaly remission. , 2002, Journal of neurosurgery.

[38]  J. Olsen,et al.  Acromegaly and cancer risk: a cohort study in Sweden and Denmark , 2002, Cancer Causes & Control.

[39]  L. Bridges,et al.  Development of acromegaly during treatment of hyperprolactinemia with bromocriptine: an unusual acidophil stem cell adenoma. , 1996, The Journal of clinical endocrinology and metabolism.

[40]  E. Laws,et al.  Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels. , 1994, Neurosurgery.

[41]  A. Barkan.  Acromegaly , 1992, Trends in Endocrinology & Metabolism.

[42]  K. Kovacs,et al.  Acidophil stem cell adenoma of the human pituitary: Clinicopathologic analysis of 15 cases , 1981, Cancer.

[43]  I. Bernabéu,et al.  Long-term outcome of multimodal therapy for giant prolactinomas , 2016, Endocrine.

[44]  M. Andersen.  Management of endocrine disease: GH excess: diagnosis and medical therapy. , 2014, European journal of endocrinology.

[45]  F. Greenway,et al.  An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: , 2010 .

[46]  S. Gibbs.  Results of Transsphenoidal Surgery in a Large Series of Patients With Pituitary Adenoma , 2006 .

[47]  F. Casanueva,et al.  Oncological Complications of Excess GH in Acromegaly , 2004, Pituitary.

[48]  D. Berry.  A therapeutic approach. , 1984, Nursing times.

[49]  J. Sneep.  With a summary , 1945 .